@keen as
Anyone making a bid at a premium will not be doing it out of the goodness of their heart.
We all know LLL is still very underpriced even with a hefty risk discount applied. No guesses required why.
Any serious bidder will not allowing the SP a free run.
They will be buying FFX because they believe they can make good money - The value gap. Getting them cheap.
Liquidity & Value? FFX holders get the LIQUIDITY, the buyer gets the VALUE
On top of that we will be paying a commission to do it. Treadstone is likely on at least 3% of the transaction, quite possibly a lot more.
Based on the above, like many here my share of the commission is a hefty amount. More if it’s a higher % - $1.50 at 5% is a whopping $1,440 per 100,000 shares.
This whole process has been nothing but an anchor on LLL SP, another disaster inflicted by the BOD on shareholders, as if we have not had to put up with enough.
Get it locked away to go to FFX holders, and the capping stops - good for LLL SP
Anyone who wants a decent stake will have to buy on market - good for LLL SP
Kill the Process ASAP in my view.
- Forums
- ASX - By Stock
- FFX
- Ann: Shareholder Update
Ann: Shareholder Update, page-137
-
- There are more pages in this discussion • 256 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add FFX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online